Intuitive Surgical (ISRG) was trading at $621.4 as of May 17, 2016. It has a 50-day moving average of $623.9 and a 200-day moving average of $562.8.
As of May 17, 2016, Intuitive Surgical’s stock was trading ~39% above its 52-week low and ~5% below its 52-week high. The company’s share price fell ~2.5% after the release of its 1Q16 earnings on April 19, 2016. The rise was triggered by higher-than-expected earnings results for the quarter.
Since then, ISRG’s stock price has fallen by ~0.9%. Intuitive Surgical has returned ~76% over the last two years. It outperformed the market represented by the S&P 500 Index, which returned ~9% during the same period.
Two years ago, the company’s stock price fell steeply amid the troubles it faced selling its da Vinci Xi surgical system. It ran into problems due to hospitals’ cost constraints and doubts over the system’s efficacy for benign hysterectomy procedures.
Peers’ stock performances
As of May 17, 2016, Intuitive Surgical’s peer companies Medtronic (MDT), Stryker (SYK), and TransEnterix (TRXC) had generated returns of 33.4%, 36.3%, and -54.4%, respectively, over the last two years.
TransEnterix recently failed to receive FDA approval for its SurgiBot system, which was expected to be a competitor to Intuitive Surgical’s da Vinci at a lower capital cost. This event led TRXC’s stock to fall by more than 21%.
The Vanguard Growth ETF (VUG) focuses on the medical device industry. Intuitive Surgical accounts for ~0.26% of VUG’s total holdings.